Abemaciclib D5
| Product Name | Abemaciclib D5 |
|---|---|
| Alternate Names | Abemaciclib Stable Isotopes, Stable Isotopes of Abemaciclib |
| CAT No. | CS-O-32774 |
| CAS No. | 1231929-97-7 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | 511.62 g/mol |
| Mol. For. | C22H27D5F2N8 |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Abemaciclib |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | CC(N1C2=CC(C3=NC(NC4=CC=C(CN5CCN(C([2H])([2H])C([2H])([2H])[2H])CC5)C=N4)=NC=C3F)=CC(F)=C2N=C1C)C |
| Canonical Smiles | CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F |
| InchIKey | UZWDCWONPYILKI-UHFFFAOYSA-N |
| Inchl | InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34) |
| IUPAC | N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Abemaciclib D5 is a chemical compound that is used in the treatment of breast cancer. It is a potent and selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6), which are enzymes involved in cell division. By inhibiting these enzymes, Abemaciclib D5 slows down the growth of cancer cells and prevents them from dividing and multiplying.
The usage of Abemaciclib D5 is primarily for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is generally administered orally, with the recommended dose being 150 mg twice daily. The dosage may vary depending on the patient's condition and response to treatment.
Chemically, Abemaciclib D5 is a deuterated version of Abemaciclib, which means that it contains five atoms of deuterium. Deuterium is a stable isotope of hydrogen that has been used in the development of drugs to improve their pharmacokinetic properties, such as bioavailability, half-life, and metabolic stability.
Abemaciclib D5 has been extensively studied in preclinical and clinical trials, and it has been shown to have a favorable safety profile. However, like any other drug, it may cause side effects, such as diarrhea, nausea, fatigue, and decreased appetite. Patients taking Abemaciclib D5 should be closely monitored by healthcare professionals to manage any adverse reactions.
Get an Instant Quote
Related Compounds
Abemaciclib D10 | Abemaciclib D8 | Abemaciclib Impurity 1 D12 | Abemaciclib D7 | Abemaciclib Impurity 1 D5 | Abemaciclib Impurity 5 D5 |